Quetiapine vs Aripiprazole: Nutrient Depletion Comparison
Compare YOUR medications' depletionsFree, 10 seconds →
At a Glance
Quetiapine blocks 25 molecular targets including histamine H1, serotonin 5-HT2A/2C, dopamine D2, and adrenergic alpha-1 receptors. The H1 and 5-HT2C blockade drives appetite stimulation and insulin resistance, creating metabolic syndrome that cascades into nutrient depletion: vitamin D sequesters in expanding adipose tissue, B vitamins are consumed by stressed glucose metabolism, and CoQ10 is depleted through mitochondrial impairment. Its sedating properties lead to widespread off-label prescribing for insomnia, exposing sleep patients to unnecessary antipsychotic-class metabolic effects.
Quetiapine has only 9% oral bioavailability with a short 6-hour half-life and 83% protein binding, requiring multiple daily doses for psychosis but often used once at bedtime for mood and sleep indications.
- ✓Uniquely effective for bipolar depression — FDA-approved indication no other atypical matches as first-line monotherapy
- ✓Powerful sedation addresses severe insomnia common in bipolar and schizophrenia patients
- ✓FAERS logs 87,111 reports with extensive real-world data across diverse psychiatric populations
- ✓6-hour half-life allows partial metabolic recovery between doses — shorter than olanzapine's 30h
- ✗25 molecular targets create one of the broadest side effect profiles of any medication
- ✗Significant weight gain (8–12 lbs first year) — second worst metabolic profile after olanzapine
- ✗Widely prescribed off-label for insomnia at low doses, exposing patients to antipsychotic-class nutrient depletion unnecessarily
- ✗Only 9% bioavailability — 91% of each dose wasted to first-pass metabolism
Bipolar depression (unique FDA-approved monotherapy indication), patients needing combined mood stabilization and sedation.
Aripiprazole's partial dopamine D2 agonism fundamentally differs from quetiapine's full antagonism — it modulates rather than blocks the dopamine signal. This creates minimal H1 histamine blockade and avoids the appetite stimulation cascade that makes quetiapine metabolically dangerous. Nutrient depletion still occurs through general antipsychotic-class effects on serotonin 5-HT2A pathways and mitochondrial function, but at dramatically lower severity without the metabolic syndrome amplifier.
Aripiprazole achieves 87% bioavailability — nearly 10x quetiapine's 9% — with a 75-hour half-life providing the most stable antipsychotic blood levels available. Takes 2–3 weeks to reach steady state.
- ✓Lowest metabolic risk of any antipsychotic — weight-neutral with minimal insulin disruption
- ✓FAERS death-associated rate of only 1.8% — dramatically lower than most antipsychotics
- ✓87% bioavailability and 75-hour half-life provide the most stable, predictable blood levels
- ✓No prolactin elevation — avoids sexual dysfunction, galactorrhea, and bone density loss from hyperprolactinemia
- ✗Not sedating — cannot replace quetiapine for patients needing sleep-promoting antipsychotic effects
- ✗Akathisia (restless agitation) is the most common side effect — can be treatment-limiting
- ✗75-hour half-life means slow onset (2–3 weeks to steady state) and slow clearance if problems develop
- ✗Less effective for acute psychotic agitation compared to sedating antipsychotics
First-line antipsychotic for patients prioritizing metabolic health, weight neutrality, and the lowest possible nutrient depletion intensity.
Feature Comparison
| Feature | Quetiapine | Aripiprazole |
|---|---|---|
| Drug Class | Atypical antipsychotic (multi-receptor antagonist) | Atypical antipsychotic (partial D2 agonist) |
| Nutrients Affected | 4 — CoQ10, vitamin D, B vitamins, metabolic | 4 — CoQ10, vitamin D, B vitamins, metabolic |
| Metabolic Severity | Significant (second worst after olanzapine) | Minimal (best in class) |
| Half-Life | 6 hours | 75 hours |
| Bioavailability | 9% | 87% |
| FAERS Reports | 87,111 total | 45,722 (1.8% death rate) |
| Weight Gain | 8–12 lbs first year | Minimal (weight-neutral) |
| Sedation | Strong (useful for insomnia) | None (may cause akathisia) |
Wondering which medication depletes less?
Check your medications free — 10 seconds →Verdict
Both affect the same four nutrient categories, but the metabolic impact is incomparable. Quetiapine's H1/5-HT2C blockade drives 8–12 lbs weight gain that cascades into vitamin D sequestration, B-vitamin depletion, and CoQ10 impairment. Aripiprazole's partial dopamine agonism avoids this metabolic cascade entirely — weight-neutral, minimal insulin disruption, 1.8% FAERS death rate. For nutrient preservation, aripiprazole is categorically superior. Quetiapine's niche is bipolar depression (where it has unique FDA-approved monotherapy evidence) and patients who need antipsychotic-level sedation. For all other indications — first-episode psychosis, MDD augmentation, bipolar maintenance — aripiprazole's metabolic safety makes it the standard first choice. Patients on quetiapine should have aggressive metabolic monitoring and vitamin D, B-complex, and CoQ10 supplementation from day one.
FAQ
References
- [1]CTD (Comparative Toxicogenomics Database): receptor binding and gene interaction profiles for both drugs across metabolic and neuronal pathways
- [2]FAERS (FDA Adverse Event Reporting System): quetiapine 87,111 reports; aripiprazole 45,722 reports with 1.8% death-associated rate
- [3]ChEMBL bioactivity database: 25 molecular targets for quetiapine; partial D2 agonist classification for aripiprazole
- [4]PubMed PMID 15741488 — Newcomer JW. Second-generation antipsychotics and metabolic effects. CNS Drugs. 2005;19(Suppl 1):1-93
- [5]PubMed PMID 19370587 — De Hert M et al. Metabolic and cardiovascular adverse effects of antipsychotic drugs. Nat Rev Endocrinol. 2012;8(2):114-126
Check your medications
Check Free →